ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
UNITY Biotechnology Inc

UNITY Biotechnology Inc (UBX)

1.245
-0.055
( -4.23% )
Updated: 14:11:35

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.245
Bid
1.24
Ask
1.25
Volume
121,759
1.22 Day's Range 1.32
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.30
Open
1.30
Last Trade
700
@
1.245
Last Trade Time
14:11:35
Financial Volume
$ 151,787
VWAP
1.2466
Average Volume (3m)
-
Shares Outstanding
14,620,671
Dividend Yield
-
PE Ratio
-0.46
Earnings Per Share (EPS)
-2.73
Revenue
-
Net Profit
-39.86M

About UNITY Biotechnology Inc

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while lea... Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
UNITY Biotechnology Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker UBX. The last closing price for UNITY Biotechnology was $1.30. Over the last year, UNITY Biotechnology shares have traded in a share price range of $ 0.00 to $ 0.00.

UNITY Biotechnology currently has 14,620,671 shares outstanding. The market capitalization of UNITY Biotechnology is $18.28 million. UNITY Biotechnology has a price to earnings ratio (PE ratio) of -0.46.

UBX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRDIGRIID Infrastructure Inc
$ 1.435
(156.25%)
133.52M
ZAPPZapp Electric Vehicles Group Ltd
$ 2.9192
(114.65%)
85.53M
MGOLMGO Global Inc
$ 0.753
(64.27%)
152.46M
RELIReliance Global Group Inc
$ 0.5631
(43.98%)
119.98M
SMXSMX Security Matters Public Company
$ 0.1635
(37.39%)
166.21M
WHLRWheeler Real Estate Investment Trust Inc
$ 2.75
(-82.51%)
140.58k
KAVLKaival Brands Innovations Group Inc
$ 2.72
(-39.56%)
998.52k
MBIOMustang Bio Inc
$ 0.5461
(-35.76%)
35.27M
NLSPNLS Pharmaceutics Ltd
$ 0.1816
(-32.77%)
13.21M
TPSTTempest Therpeutics Inc
$ 1.955
(-31.40%)
29.64M
NVDANVIDIA Corporation
$ 132.84
(-2.02%)
387.4M
NKLANikola Corporation
$ 0.3501
(-27.20%)
206.72M
SMXSMX Security Matters Public Company
$ 0.1635
(37.39%)
166.21M
MGOLMGO Global Inc
$ 0.753
(64.27%)
152.46M
GRDIGRIID Infrastructure Inc
$ 1.435
(156.25%)
133.52M

UBX Discussion

View Posts
surfkast surfkast 4 weeks ago
I was lucky a few years ago and then it crashed and never recouped. I am now in IOVA. Flipped it twice already and just bought back in.
šŸ‘ļø0
BooDog BooDog 4 weeks ago
This was on my watchlist so I must have played it at some point. Glanced at it today and thought it might be good for a swing but passed on it. It needs something to go in their favor to get some momentum.
šŸ‘ļø0
surfkast surfkast 4 weeks ago
This company looked promising but then they got stagnant. Plus they keep, issuing shares to pay employees,
šŸ‘ļø0
BooDog BooDog 4 weeks ago
Thought about UBX here, 1.45 - 1.47, couldn't push the button. Looks like a duck, smells like a duck...


Maybe around the $? Either way, i'll miss out.
šŸ‘ļø0
surfkast surfkast 1 month ago
I give up. IOVA for me. Just flipped for,$40,000 on a pop.
šŸ‘ļø0
surfkast surfkast 4 months ago
This company is dead and has been for over a year now. All they do is keep issuing shares to pay their employees.
šŸ‘ļø0
Monksdream Monksdream 4 months ago
UBX under $2
šŸ‘ļø0
surfkast surfkast 4 months ago
Glad I dumped this one and got into IOVA!
šŸ‘ļø0
Jayzp Jayzp 1 year ago
Ther meme stock..good news

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
šŸ‘ļø0
MedicallyApproved658 MedicallyApproved658 1 year ago
Wedge forming
šŸ‘ļø0
surfkast surfkast 1 year ago
I also did, but now I am and have been just watching.
šŸ‘ļø0
Pisd Pisd 1 year ago
Made money UBX$..now back on the watch list, gl...
šŸ‘ļø0
surfkast surfkast 1 year ago
Until they have a success, temporary moves up then insiders dumping for their pay.
šŸ‘ļø0
EDobbs40 EDobbs40 1 year ago
Starting to climb back up.
šŸ‘ļø0
surfkast surfkast 1 year ago
Not anymore.
šŸ‘ļø0
EDobbs40 EDobbs40 1 year ago
Chief Medical Officer leaving, trial was a bust. Does anyone have hopesin this one making a comeback?
šŸ‘ļø0
Pisd Pisd 1 year ago
Unity Biotechnology Shares Plumb New Depths After Study Setback >UBX
11:44 am ET March 27, 2023 (Dow Jones) Print

By Colin Kellaher

Shares of Unity Biotechnology Inc. lost more than half of their value and hit an all-time low Monday after the biotechnology company's lead pipeline candidate UBX1325 missed a key goal in a Phase 2 study in wet age-related macular degeneration, or wet AMD.

Unity said UBX1325 failed to achieve non-inferiority versus aflibercept at 24 weeks on the best corrected visual acuity test.

In a research note, Mizuho analysts Salim Syed and Erik Lavington said they cut their price target on Unity shares to $6 from $12 after removing wet AMD, saying they don't see a likely viable go-forward for UBX1325 in the indication.

Mizuho also lowered its probability-of-success forecast for UBX1325 in diabetic macular edema to 25% from 33%.

Unity said it plans to assess and optimize its resource allocation for future development of UBX1325 after it fully analyzes the study results.

The Mizuho analysts said Unity's $75 million of net cash is worth roughly $5 of their $6 price target, and they noted that the market may not want full credit for the cash due to continued spending by the South San Francisco, Calif., company.

Unity shares were recently changing hands at $2.00, down nearly 52% and reaching their lowest level since the company went public in May 2018.
šŸ‘ļø0
Pisd Pisd 1 year ago
Trial was positive, up goes the stock imo ...
šŸ‘ļø0
surfkast surfkast 1 year ago
Bad for investors.
šŸ‘ļø0
Pisd Pisd 1 year ago
Better for bottom line to pay employees w/shares ...
šŸ‘ļø0
Meangene818 Meangene818 1 year ago
This has got to be the ugliest chart ever, Iā€™m gonna grab some. Lol
šŸ‘ļø0
surfkast surfkast 1 year ago
Amazon revenue for the twelve months ending December 31, 2022 was $513.983B

SMH
šŸ‘ļø0
Pisd Pisd 1 year ago
Right but Amazon does that too, soooo ??, had bad trial result, gl...
šŸ‘ļø0
surfkast surfkast 1 year ago
How can one make any money when there is constant dilution as the company pays its employees in shares?
šŸ‘ļø0
Pisd Pisd 1 year ago
..time to reload, $3.80's.. UBX$ money maker ...
šŸ‘ļø0
Pisd Pisd 1 year ago
https://ih.advfn.com/stock-market/NASDAQ/unity-biotechnology-UBX/stock-news/90195384/amended-statement-of-ownership-sc-13g-a
šŸ‘ļø0
Pisd Pisd 1 year ago
UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
8:00 am ET February 9, 2023 (Globe Newswire)

-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET-

-Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023-

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325, as a potential treatment solution to address the unmet medical need present in age-related diseases of the eye on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET. Robert B. Bhisitkul, M.D., Ph.D., of University of California San Francisco School of Medicine will review data from the Phase 2 BEHOLD study in diabetic macular edema, followed by an update on upcoming data readouts from the Phase 2 ENVISION study in patients with wet age-related macular degeneration. The Company expects to have 16- and 24-week safety and efficacy data from the ENVISION study in the first quarter of 2023.

A live question and answer session will follow the formal presentation. The webcast can be accessed in the "Investors and Media" section of our website, www.unitybiotechnology.com, under "Events & Presentations" or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the "Investors & Media" section of our website, under "Events and Presentations."

About UNITY

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
šŸ‘ļø0
Pisd Pisd 1 year ago
I see the form 4's, but to me insiders sell the free shares and make free money I get that, but when can I know it's aggregious?, How can I find out they don't get a salary but instead get paid in shares?..

Appreciate any help or advice.

Thanks
šŸ‘ļø0
surfkast surfkast 1 year ago
Employees are getting paid with free trading shares. In investors have to be careful and aware as the PPS can suddenly drop.
šŸ‘ļø0
surfkast surfkast 1 year ago
Employees are getting paid with free trading shares. In investors have to be careful and aware as the PPS can suddenly drop.
šŸ‘ļø0
Pisd Pisd 1 year ago
Q., what is your go to for insider trading info, form 4, bal sheet 10q?, scheduled trades, maybe all of the above, because honest and surely intentionally it's hard for the homegamer to do the calculations, how many shares and when etc.

Thanks for any thoughts, seems important to learn more about these days..
šŸ‘ļø0
Pisd Pisd 1 year ago
doubled down today.. UBX$ ...
šŸ‘ļø0
surfkast surfkast 1 year ago
GLTY.
šŸ‘ļø0
Pisd Pisd 1 year ago
Bought back $4, running up imo.. UBX$...
šŸ‘ļø0
Pisd Pisd 1 year ago
Sold for helpful profit today, monitoring.. UBX$...
šŸ‘ļø0
surfkast surfkast 1 year ago
Moving up I see.
šŸ‘ļø0
Pisd Pisd 1 year ago
..keep going lol.. UBX$ ...
šŸ‘ļø0
surfkast surfkast 2 years ago
Not doing well.
šŸ‘ļø0
Pisd Pisd 2 years ago
Let's gooo !!!!!!! ... $4 c'mon.. ubx$$...
šŸ‘ļø0
Pisd Pisd 2 years ago
...mad money pick here, gl.. UBX$...
šŸ‘ļø0
surfkast surfkast 2 years ago
They are paying employees with shares.
šŸ‘ļø0
Pisd Pisd 2 years ago
Seems they chew up whatever you put down..patient, UBX$...
šŸ‘ļø0
Pisd Pisd 2 years ago
Can't go down forever, split wiped out now.. UBX$...
šŸ‘ļø0
surfkast surfkast 2 years ago
I nailed it once. Watching for now. The biggest problem is they are paying employees with shares.
šŸ‘ļø0
BooDog BooDog 2 years ago
I just added this to my watchlist. Need to dd. eom
šŸ‘ļø0
Pisd Pisd 2 years ago
..important phase II solution Macular Edema.. UNITY Biotechnology Announces 24-Week Data From Phase 2 BEHOLD Study Of UBX1325 In Patients With Diabetic Macular Edema

7:01 am ET November 1, 2022 (Benzinga)

A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment.

UBX1325 maintained stabilization of retinal structure, as measured by central subfield thickness (CST) at 24 weeks, as compared to worsening from baseline in sham-treated patients.

The proportion of rescue-free patients in the UBX1325-treated arm was 59.4% at 6 months after a single injection, as compared to only 37.5% in the sham-treated arm.

UNITY to host investor call with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, today,
šŸ‘ļø0
Pisd Pisd 2 years ago
Only 14m shares now, 24m traded today lol.. UBX$...
šŸ‘ļø0
Pisd Pisd 2 years ago
Buyer of "sell-the-news" a bargain at $3 imo.. UBX$...
šŸ‘ļø0
surfkast surfkast 2 years ago
.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $6.67 average price target, implying a 1,683.42% upside from current levels.
https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-unity-biotechnology-ubx?utm_source=advfn.com&utm_medium=referral
šŸ‘ļø0
surfkast surfkast 2 years ago
.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $6.67 average price target, implying a 1,683.42% upside from current levels.
https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-unity-biotechnology-ubx?utm_source=advfn.com&utm_medium=referral
šŸ‘ļø0

Your Recent History

Delayed Upgrade Clock